Biomechanical changes in the liver tissue induced by a mouse model of multiple sclerosis (EAE) and the effect of anti-VLA-4 mAb treatment

被引:2
|
作者
Pyka-Fosciak, G. [1 ]
Zemla, J. [2 ]
Lekki, J. [2 ]
Wojcik, B. [1 ]
Lis, G. J. [1 ]
Litwin, J. A. [1 ]
Lekka, M. [2 ]
机构
[1] Jagiellonian Univ Med Coll, Dept Histol, Kopernika 7, PL-31034 Krakow, Poland
[2] Polish Acad Sci, Dept Biophys Microstruct, Inst Nucl Phys, PL-31342 Krakow, Poland
关键词
Multiple sclerosis (MS); Experimental autoimmune encephalomyelitis; (EAE); Liver; Natalizumab; Inflammation; Atomic force microscopy; Rheology; PRIMARY BILIARY-CIRRHOSIS; TRANSIENT ELASTOGRAPHY; NONINVASIVE ASSESSMENT; STIFFNESS MEASUREMENT; MECHANICAL RESPONSE; FIBROSIS; HEPATITIS; NATALIZUMAB; ELASTICITY; DIAGNOSIS;
D O I
10.1016/j.abb.2022.109356
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Experimental autoimmune encephalomyelitis (EAE) is a mouse model of demyelinating diseases, such as multiple sclerosis (MS). MS can be accompanied by autoimmune hepatitis. In this study, nanomechanical, biorheological and histological examinations were carried out by atomic force microscopy (AFM), rheology, and immunofluorescence microscopy to investigate changes in the liver tissue of EAE mice and the effect of natalizumab, a monoclonal antibody against alpha 4-integrin (VLA-4) cell adhesion molecule, used in MS therapy. Liver samples collected from EAE mice in three successive phases of the disease showed inflammatory changes manifested by leukocyte infiltrations and elevated levels of proinflammatory cytokine IL-1 beta. Liver stiffness and viscoelasticity increased in the onset phase of EAE, decreased in the peak phase and increased again in the chronic phase to reach the highest values. These changes were not associated with inflammation parameters which increased in the peak phase and decreased to the lowest values in the chronic phase. Moreover, anti-VLA treatment, which reduced the inflammation parameters, had an ambiguous effect on stiffness and viscoelasticity: it increased them in the peak phase but decreased in the chronic phase. The observed discrepancies can result from a complex network of interactions between inflammation and fibrosis, as well as between liver cells and the extracellular matrix influencing the biomechanical properties of the liver tissue.
引用
收藏
页数:8
相关论文
共 25 条
  • [1] Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis
    Pyka-Fosciak, Grazyna
    Lis, Grzegorz J.
    Litwin, Jan A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
  • [2] Osteopontin expression and the effect of anti-VLA-4 mAb treatment in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis
    Pyka-Fosciak, Grazyna
    Litwin, Jan A.
    Lis, Grzegorz J.
    FOLIA NEUROPATHOLOGICA, 2023, 61 (02) : 129 - 137
  • [3] Therapeutic uses of anti-a4-integrin (anti-VLA-4) antibodies in multiple sclerosis
    Schwab, Nicholas
    Schneider-Hohendorf, Tilman
    Wiendl, Heinz
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 47 - 53
  • [4] RETRACTED: Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis (Retracted Article)
    Ramroodi, Nourollah
    Khani, Masood
    Ganjali, Zohre
    Javan, Mohammad Reza
    Sanadgol, Nima
    Khalseh, Roghayeh
    Ravan, Hadi
    Sanadgol, Ehsan
    Abdollahi, Mohammad
    IMMUNOLOGICAL INVESTIGATIONS, 2015, 44 (07) : 694 - 712
  • [5] Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b+CD4+ T Cells in the CNS during Progressive EAE
    Mindur, John E.
    Ito, Naoko
    Dhib-Jalbut, Suhayl
    Ito, Kouichi
    PLOS ONE, 2014, 9 (06):
  • [6] The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis
    Robier, Christoph
    Amouzadeh-Ghadikolai, Omid
    Bregant, Claudia
    Diez, Josef
    Melinz, Klaus
    Neubauer, Manfred
    Quasthoff, Stefan
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (09) : 1269 - 1272
  • [7] Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation
    Vainio, S. K.
    Dickens, A. M.
    Tuisku, J.
    Eskola, O.
    Solin, O.
    Loyttyniemi, E.
    Anthony, D. C.
    Rinne, J. O.
    Airas, L.
    Haaparanta-Solin, M.
    EJNMMI RESEARCH, 2019, 9 (1)
  • [8] Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation
    S. K. Vainio
    A. M. Dickens
    J. Tuisku
    O. Eskola
    O. Solin
    E. Löyttyniemi
    D. C. Anthony
    J. O. Rinne
    L. Airas
    M. Haaparanta-Solin
    EJNMMI Research, 9
  • [9] Anaphylaxis and Mortality Induced by Treatment of Mice with Anti-VLA-4 Antibody and Pertussis Toxin
    Ji, Niannian
    Rao, Nagarjun
    Guentzel, Neal M.
    Arulanandam, Bernard P.
    Forsthuber, Thomas G.
    JOURNAL OF IMMUNOLOGY, 2011, 186 (05) : 2750 - 2756
  • [10] EFFECT OF NATALIZUMAB TREATMENT ON METALLOPROTEINASES AND THEIR INHIBITORS IN A MOUSE MODEL OF MULTIPLE SCLEROSIS
    Pyka-Fosciak, G.
    Lis, G. J.
    Litwin, J. A.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2020, 71 (02): : 265 - 273